CERVOMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.5 USD | -2.33% |
|
-9.46% | +103.15% |
| Jul. 01 | CervoMed Inc.(NasdaqCM:CRVO) added to Russell Small Cap Completeness Index | CI |
| Jul. 01 | CervoMed Inc.(NasdaqCM:CRVO) added to Russell Microcap Growth Index | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 43.3 | 127.9 | - | - |
| Enterprise Value (EV) 1 | 35.5 | 88.33 | 23.23 | 73.03 |
| P/E ratio | -9.3 x | -9.26 x | -6.81 x | -5.2 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 6.06 x | 14.8 x | 24.9 x | - |
| EV / Revenue | 4.97 x | 10.2 x | 4.53 x | - |
| EV / EBITDA | -4.54 x | -5.59 x | -0.6 x | -1.35 x |
| EV / FCF | -4.77 x | -5.66 x | -0.75 x | -1.69 x |
| FCF Yield | -21% | -17.7% | -133% | -59.1% |
| Price to Book | 5.87 x | 2.96 x | 1.78 x | 3.26 x |
| Nbr of stocks (in thousands) | 5,675 | 8,254 | - | - |
| Reference price 2 | 7.630 | 15.50 | 15.50 | 15.50 |
| Announcement Date | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 7.145 | 8.633 | 5.133 | - |
| EBITDA 1 | - | -7.813 | -15.8 | -39 | -54 |
| EBIT 1 | - | -7.813 | -14 | -27.47 | -38.8 |
| Operating Margin | - | -109.35% | -162.16% | -535.07% | - |
| Earnings before Tax (EBT) 1 | - | -2.172 | -13.5 | -27.2 | -38.53 |
| Net income 1 | -5.803 | -2.172 | -13.5 | -27.2 | -38.53 |
| Net margin | - | -30.4% | -156.37% | -529.87% | - |
| EPS 2 | -1.290 | -0.8200 | -1.673 | -2.277 | -2.983 |
| Free Cash Flow 1 | - | -7.45 | -15.6 | -30.9 | -43.15 |
| FCF margin | - | -104.27% | -180.7% | -601.95% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/13/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.526 | 2.491 | 2.347 | 2.1 | 2.1 | 2.067 |
| EBITDA 1 | - | -2.48 | -2.595 | -3.9 | -4.4 | -5 |
| EBIT 1 | -2.675 | -2.48 | -2.595 | -3.267 | -3.8 | -4.333 |
| Operating Margin | -175.25% | -99.59% | -110.55% | -155.56% | -180.95% | -209.68% |
| Earnings before Tax (EBT) 1 | 2.15 | -2.362 | -2.514 | -3.133 | -3.7 | -4.2 |
| Net income 1 | 2.15 | -2.362 | -2.514 | -3.133 | -3.7 | -4.2 |
| Net margin | 140.87% | -94.85% | -107.12% | -149.21% | -176.19% | -203.23% |
| EPS 2 | 0.6500 | -0.9500 | -0.4100 | -0.3667 | -0.4267 | -0.4767 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/13/23 | 3/29/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 7.79 | 39.6 | 105 | 54.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -7.45 | -15.6 | -30.9 | -43.2 |
| ROE (net income / shareholders' equity) | - | - | -61.5% | -51.4% | -63.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | 1.300 | 5.230 | 8.710 | 4.760 |
| Cash Flow per Share 2 | - | -2.800 | -1.860 | -2.640 | -3.640 |
| Capex 1 | - | - | 0.8 | 2 | 2 |
| Capex / Sales | - | - | 9.27% | 38.96% | - |
| Announcement Date | 7/13/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.5
USD
Average target price
55
USD
Spread / Average Target
+254.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +103.15% | 128M | |
| +16.61% | 122B | |
| +17.75% | 112B | |
| +17.23% | 25.91B | |
| -24.11% | 19.33B | |
| -18.56% | 16.17B | |
| -18.47% | 15.6B | |
| -47.75% | 14.65B | |
| +57.35% | 14.34B | |
| +5.62% | 14B |
- Stock Market
- Equities
- CRVO Stock
- Financials CervoMed Inc.
